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Schistosomiasis is a debilitating disease that represents a major health problem in at least
74 tropical and subtropical countries. Current disease control strategies consist mainly of
chemotherapy, which cannot prevent recurrent re-infection of people living in endemic
area. In the last decades, many researchers made a remarkable effort in the search for
an effective vaccine to provide long-term protection. Parasitic platyhelminthes of Schisto-
soma genus, which cause the disease, live in the blood vessels of definitive hosts where
they are bathed in host blood for many years. Among the most promising molecules as
vaccine candidates are the proteins present in the host–parasite interface, so numerous
tegument antigens have been assessed and the achieved protection never got even close
to 100%. Besides the tegument, the digestive tract is the other major site of host–parasite
interface. Since parasites feed on blood, they need to swallow a considerable amount
of blood for nutrient acquisition. Host blood ingested by schistosomes passes through
the esophagus and reaches the gut where many peptidases catalyze the proteolysis of
blood cells. Recent studies show the emergence of antigens related to the parasite blood
feeding, such as esophageal gland proteins, proteases, and other proteins related to nutri-
ent uptake. Herein, we review what is known about Schistosoma mansoni digestive tract
proteins, emphasizing the ones described as potential vaccine candidates.
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INTRODUCTION
Schistosomiasis is considered the most important human
helminth infection in terms of global mortality in developing
countries. It is estimated that schistosomiasis causes 280,000
deaths in Sub-Saharan Africa alone (1, 2). The morbidity rates
are also high and this disease is responsible for the loss of up
to 4.5 million DALYs (disability adjusted life years) annually (3).
Many countries have been investing in intervention strategies
based on mass drug administration (4, 5). Nonetheless, the mas-
sive treatment has not decreased the endemicity due to constant
re-infection of people and low quality of sanitary conditions in
endemic areas (6–8) and yet, around 800 million people live in
risk areas in 74 developing countries, of which at least 200 million
people are infected (3, 9).
Many scientists search for a feasible vaccine against schisto-
somiasis; they believe this is the best strategy for reducing the
disease transmission and morbidity. If a vaccine induced even a
partial reduction in worm burdens it would considerably reduce
pathology and limit parasite transmission (10, 11). Preventive vac-
cination would clearly overcome re-infection problems avoiding
the need for repeated treatments of people living in endemic areas.
As a result, vaccine strategies represent an essential component as
an adjunct to chemotherapy for the control of schistosomiasis.
The improvement in understanding of the immune response to
schistosomes suggests that development of a vaccine is possi-
ble (5). In the search for vaccine targets, proteins located at the
parasite/host interface are likely to be the most important, since
they are commonly associated with mechanisms of escape from
the host immune system or other adaptation to parasitism (12).
The two major surfaces that constitute these interfaces are the
outer tegument and the gastrodermis – gut lining (13). The tegu-
ment has been the major target of vaccine development. Recently,
however, scientists are also focusing on schistosome gut and its
secreted products. Protection studies demonstrate the potential
of an esophageal gland secreted protein, gut proteases, and other
gastrodermis proteins to be exploited for vaccine development.
Throughout this work, we will review the digestive tract of Schis-
tosoma mansoni and also present and discuss recent studies in
vaccine development.
DIGESTIVE TRACT
The digestive tract of S. mansoni consists of the oral sucker, the
esophagus, which is surrounded by the esophageal gland in its
posterior portion and the blind-ended gut. Schistosome mouth is
subapical and opens through the oral sucker, which is the begin-
ning of the digestive tract in the anterior extremity of the worm.
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The oral sucker is a funnel-shaped vent covered by the tegument
and bears thousands of spines, which extend up to the esophagus
(14–16). The esophagus immediately succeeds the mouth opening
and connects the sucker to the gut. It is a short tube that is invested
by longitudinal and circular muscle fibers and two stronger circu-
lar muscle act as sphincters that control the entrance of blood (14,
17, 18). The esophagus is covered by an extension of the syncytial
tegument with higher specialized surface architecture, specially
focused in blood processing, and also an enormous membrane
expanded into plates (17). The posterior half of the esophagus is
surrounded by the esophageal gland that releases secretions into
its lumen to process ingested host blood (17). The esophagus ends
into the beginning of the gut. Then, posterior to the ventral sucker,
the gut bifurcates into two lateral portions, which run either side
of the reproductive organs and rejoin posterior to them, form-
ing again a single portion that continues to the posterior end of
the worm body. Since the gut is blind-ended, secretion of products
might occur by regurgitation through the mouth (19, 20). The sur-
face of the gut is a syncytial epithelial layer known as gastrodermis.
Although gastrodermis is syncytial like the tegument, its cyto-
plasm differs by the presence of numerous mitochondria, nuclei,
and biosynthetic machinery, with an active Golgi apparatus, a well-
developed granular endoplasmic reticulum and numerous vesicles
(19–21). Besides that, the gut syncytium is extended by the pres-
ence of fine cytoplasmic lamellae that characterize its absorptive
nature (22, 23).
The primary function of the schistosome digestive tract is to
digest macromolecules acquired from the blood of the mammalian
host, and to absorb the soluble products (24). To live and repro-
duce inside the host, the mature, blood feeding worms use amino
acids derived from degradation of serum proteins and lysed ery-
throcytes. Previous studies suggest that lysosomes directly secrete
their contents into the gut lumen to digest incoming plasma
(22, 24). The digestion process is presumed to be predominantly
extracellular with the final stages possibly intracellular (22, 24,
25). Several peptidases are employed in processing and acquisi-
tion nutrients provided by host blood (26–28). Carrier proteins
sequester essential organic and inorganic nutrients for uptake into
the gastrodermis and the accumulated products are periodically
eliminated from the blind-ending gut by regurgitation (22, 24).
The structure of the gastrodermis has been well documented by
transmission and scanning electron microscopic studies (19–21),
but its protein composition has yet to be fully explored.
PROTEOMIC ANALYSES
While the tegument has been the major target of characterization
studies of S. mansoni for many years, the schistosome gastrodermis
is a difficult target since it is inaccessible, what makes it pretty hard
to collect samples. An alternative technique to have some evidences
about digestive proteins is the collection of worms’ vomit, what is
also difficult because the worms do not open their mouth easily in
culture (22). The very first proteomic study on the vomit induced
regurgitation in adult worms by osmotic shock with distilled water.
Although this technique presents some contaminations from other
tissues, it provides with at least an idea of gut contents. Some host
proteins (hemoglobin, immunoglubolin (Ig)G, and serum albu-
min) were identified as well as worm antioxidants [superoxide
dismutase (SOD) and thioredoxin] and proteins related to fatty
acid absorption (lysophospholipase and fatty acid binding protein
Sm14) (29). Biochemical analyses on vomit obtained either by
osmotic or temperature shock demonstrated enzymatic activity,
confirming that schistosomes utilize proteases to digest hemoglo-
bin and host serum proteins (28, 30). Another proteomic study
extended significantly the list of constituents secreted into the
schistosome gut lumen as part of the blood feeding process. The
authors induced the regurgitation by both temperature shock
and protein starvation and the vomit contents were analyzed
through electrophoresis followed by mass spectrometry. A total
of 71 distinct proteins were identified, among them many pro-
teases (cathepsins B1, C and S/L, asparaginyl peptidase and two
proline carboxypeptidases, pro-X carboxylpeptidase, and dipep-
tidylpeptidase II), protease inhibitors (serpin and α2 macroglob-
ulin), a series of lysosomal proteins (lipid-binding saposins and
cholesterol-binding NPC-2), ion transporters (ferritins and calu-
menin), and also the previously identified antioxidants (SOD and
thioredoxin) (24). The authors suggest that, due to the morpho-
logical changes in the gastrodermis and presence of cytoplasmic
proteins (such as Sm14), parasite vomitus contents have contami-
nation as a result of worm damage (24). Besides vomitus analyses,
Nawaratna and colleagues (23) used a novel technique, the laser
capture microdissection to recover the gut epithelium from tis-
sue sections for analysis of gene expression by RT-PCR. This
study identified 121 up-regulated transcripts, as expected, pro-
teases (cathepsins A, B, D2, and L), lysosomal proteins (saposins,
NPC-2, LAMP acid lipase, and phospholipase A2), transporters
(Ca2+ ATPase, phospholipid transporter, and amino acid trans-
porter), and the antioxidant SOD were identified, in agreement to
proteomic investigations (23).
TARGETING THE GUT
The relationship between the parasite and its host is largely nutri-
tional, involving the unidirectional transfer of nutrients. In this
context, schistosome seeking for food has been the primary selec-
tion pressure to initiate the evolution of host–parasite association
(31, 32). Schistosomes not only feed on blood, but are bathed
in their food. Adult male S. mansoni is estimated to ingest some
39,000 erythrocytes hourly, while the female, due to egg produc-
tion, requires 10 times more, 330,000 erythrocytes hourly (33). In
S. mansoni, the lysis of blood cells takes place exclusively in the
digestive tract; it begins in the esophagus, where the esophageal
gland secrets digestive enzymes and erythrocytes are rapidly lysed
(15, 17). Then, peristaltic movements pass lysed cells down into
the anterior gut and, finally the gut lumen takes up the essential
nutrients (20).
Blood is essential to worm survival since it provides a consistent
and renewable nutrient resource (31). Eventual impairments to
blood processing would compromise parasite development inside
the host leading them to death through starvation. There are at
least two evidences showing this phenomenon. First, the treatment
of infected mice with cysteine protease inhibitors not only reduces
significantly worm burden but it also inhibits egg production by
females. Authors believe that inhibitors arrest hemoglobin degra-
dation causing obstruction of the feeding activity and nutrient
uptake (34,35). Besides, the elimination of S. mansoni adult worms
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by rhesus macaques seems to be related to gut damage. Surviving
moribund worms had alterations in their intestinal epithelium and
absence of food in the gut lumen, pointing to worm starvation.
The authors suggest that blocking antibodies impact on nutrient
uptake by both gut and tegument (36). In this context, inter-
ventions that block blood processing reveal new anti-schistosome
targets for schistosomiasis control and so, the digestive tract and
its secretions appear to be a great source of key antigens.
ESOPHAGEAL GLAND AND Sm10.3 AS VACCINE CANDIDATE
The esophageal gland is a bi-lobed structure that lies around
the posterior esophagus. The first morphology study on the
esophageal gland, in the late 1970s, suggested its function in
initial blood digestion (15). Recently, a detailed morphological
and functional study on this gland confirmed the central role
of esophagus in blood processing, not acting simply as a con-
duit (17). The architecture of the esophageal gland comprises as
many as 1000 cell bodies, each connected to posterior esopha-
gus by microtubule-lined extensions. Cell bodies are specialized
in protein production and export, they synthesize large numbers
of crystalloid vesicles and release their contents into the lumen
(17, 37). Esophageal gland secretions are responsible, among other
activities, for initiating hemolysis and blood digestion. Erythro-
cytes are lysed upon their entry to the posterior esophagus and
very few intact cells are seen beyond that point (17, 24). Besides,
these secretions may also act neutralizing host immune effectors
and contributing to parasite survival. Leukocytes are somehow
tethered in the posterior lumen in variable states of degeneration
(13, 17, 19).
Micro exon gene (MEG) proteins 4.1, 4.2, and 14 (38) and also
venom allergen-like (VAL) protein 7 (39) are some of the proteins
identified in the esophageal gland (17). Recent study demon-
strated preliminary evidence that MEG-4.1, also termed Sm10.3,
induces erythrocyte agglutination in vitro, what could be related
to erythrocyte digestion (40). Besides proteomic studies, a tran-
scriptional analysis of esophageal gland revealed that more than
120 genes are differentially up-regulated there. The great majority
of transcripts identified code for proteins related to binding or
hydrolase activities, which may be important to nutrient uptaking
and red cell lysis and catabolism (41).
Sm10.3 antigen was used in vaccine development against schis-
tosomiasis in the murine model. When formulated with Freund’s
adjuvant, this antigen induced a mixed Th1/Th2-type response,
as IFN-γ, TNF-α, and low levels of IL-5 were detected in the
supernatant of cultured splenocytes (40). The vaccination also
reduced in 32% the worm burden and ameliorated liver pathol-
ogy, since 43.6% less eggs were found in the liver and there was a
significant reduction in the number, size and fibrosis of granulo-
mas, 23.8, 11.8, and 39.8%, respectively. This data suggest that
Sm10.3 is a potential candidate for vaccine development (40).
These findings, together with the detection of host IgG binding
in schistosome esophagus, suggest that esophageal gland proteins
are attractive vaccine candidates, not only because they mediate
initial feeding process, but also because antibodies targeting such
proteins would not face the hostile acid proteolytic environment
in the gut (17).
GUT PROTEASES
Schistosome proteases are involved in a vast range of essential
processes such as invasion, migration, feeding, reproduction, acti-
vation, and evasion of immune system [reviewed in Ref. (26, 42)].
Genomic studies identified at least 250 peptidases in the genome
of S. mansoni (43, 44). In the feeding context, many proteases
have been identified in the regurgitated gut contents by biochem-
ical and proteomic analysis (24, 30). In addition, several studies
confirm the presence of proteases in the gastrodermis by immuno-
cytochemistry and point out the roles of cysteine endopeptidases,
cathepsin L, cathepsin D, cathepsin B, asparaginyl endopeptidase,
and metalloproteases in hemoglobin and serum albumin degra-
dation and processing (45–48). The great amount of proteases in
the gut provides significant redundancy in blood protein degra-
dation (27). Since S. mansoni gut proteases have a vital role in
blood processing researchers believe that they are promising vac-
cine candidates and some of them have already been tested (26,
42, 49, 50).
Schistosoma mansoni cathepsin-B1 (SmCB1) is the most abun-
dant papain-like cysteine peptidase in the parasite gastroder-
mis (51), it was first localized in the parasite gut lumen, how-
ever, another study hypothesized that this protein could be also
expressed in the cecum and protonephridia of cercariae (52).
Immunological studies with schistosomiasis patients suggested
that SmCB1 is an immunodominant target of the immune
response during pre-patent schistosome infection since authors
demonstrated that SmCB1 is targeted by IgG and IgE specific anti-
bodies (53). El Ridi and colleagues (50) evaluated the potential
of active SmCB1 as vaccine with its inbuilt adjuvanticity or as
adjuvant to another known candidates (54). In the first situa-
tion, SmCB1 reduces significantly worm burden (66–73%), eggs
in liver (51%), and in small intestine (25%). However, when
SmCB1 is incubated with proteinase-inhibitor prior to immu-
nization, the levels of protection decrease significantly, pointing
out the importance of the peptidase activity in protective poten-
tial. The immunization with active form of SmCB1 by itself also
induces the production of high levels of IL-4, IL-5, and IL-13
and high titers of IgG, IgG1, and IgG2b (54). Besides being
a promising vaccine target, SmCB1 also acts as an adjuvant,
since it increases the protection provided by immunization with
other proteins, such as glyceraldehyde 3-phosphate dehydrogenase
and peroxiredoxin-multiple antigen peptide, from<10%, formu-
lated in Th1 adjuvants, to up to 84%, formulated with SmCB1
(54, 55).
The protein Sm32 is an asparaginyl peptidase (SmAE) mem-
ber of the legumain family that, probably, cleaves zymogens of
proteinases involved in hemoglobin degradation (56–58). Its acti-
vation is an autocatalytic event and it is related to a loss of a
C-terminal portion and an N-terminal pro-domain, what reduces
the protein from 50 kDa to approximately 32 kDa (59). Several
peptides of SmAE were chemically synthesized and,when adminis-
trated in a Freund’s formulation, showed relative immunogenicity
in rabbits and mice, in particular the hydrophilic regions of the
molecule (56, 57). When SmAE was evaluated as DNA vaccine, it
elicited a significant humoral response and egg count reduction
(32%), but it failed to reduce the entire worm burden (60).
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Cathepsin D (SmCD),an aspartic protease, seems to be involved
in hemoglobin process in S. mansoni (28, 61). Schistosomula
treated with RNAi to SmCD were unable to develop and sur-
vive in mice, indicating the crucial functions of this protease in
parasite maintenance (48). Two SmCD peptides formulated with
lipid core scaffold (LCS) elicit a humoral response in mice. The
anti-SmCD antibodies recognize the native SmCD in adult worms
protein extracts, and almost abrogate its enzymatic activity in vitro,
pointing out the potential of this protein as a vaccine target (62).
OTHER GUT PROTEINS AS VACCINE TARGETS
SUPEROXIDE DISMUTASE
Immunolocalization assays demonstrated the antioxidant enzyme
Cu/Zn SOD in the two major host–parasite interfaces: schisto-
some tegument and gastrodermis. The localization of this protein
suggests the development of parasite antioxidant mechanisms to
protect themselves against the host cellular response and also
against hemoglobin oxidation products, respectively (63). Schis-
tosome SOD was also detected in proteomic analyses of worm’s
vomit and transcriptional analysis of digestive tract (23, 24, 29).
DNA vaccination strategies using Cu-Zn SOD cDNA protected
mice from S. mansoni infection reducing the worm burden up to
54%; two SOD peptides were also tested and reduced worm burden
from 31 to 51% (64). In another vaccination experiment, one SOD
peptide, CT-SOD, also formulated as DNA vaccine, induced a Th1-
immune response and significantly decreased worm burden (36–
43%) after surgical transfer of adult worms into the mesenteric
veins of immunized mice (65). A cross-reactivity study demon-
strated that mice anti-SmSOD antibodies or infected individual
sera do not recognize human SOD in its native form, meaning
that SmSOD could serve as a basis for developing a vaccine against
schistosomiasis (66).
SYNTENIN
In a recent study, schistosome syntenin (SmSynt), a PDZ-
domain protein, was localized in the gastrodermis of S. mansoni,
even though none of the proteomic and transcriptional studies
identified this protein at this location (67). The role the protein
plays in the natural biology of the parasites remains unclear since
knocking down the expression of the SmSynt gene yielded no
clear phenotype in vitro. However, syntenin is involved in many
cellular processes in mammalian cells, among them, cellular traf-
ficking and biogenesis of small extracellular vesicles, what could be
also its function in schistosome digestive tract. The recombinant
SmSynt seems to be a relevant vaccine target since it induces the
production of IgG antibodies and Th1-cytokines likely important
in disease control. Mice vaccinated with the recombinant protein
induced 30–37% of worm burden reduction. A reduction in liver
damage was also noted in vaccinated versus control mice, 38–43%
reduction in the number, and 35–37% reduction in the area of
liver granulomas (67).
SAPOSIN
Four proteins possessing the characteristic saposin domain were
identified in schistosome vomit (24). Saposins bind sphingolipids,
facilitating their degradation by ceramidases and they also bind
other lipids, sequestering them in the gut lumen for trans-
port/uptake into the cells (24, 68). A gut saposin-like protein
(SmSLP-1) has proven to be immunogenic since antibodies from
infected individuals recognized its recombinant form, however, it
was ineffective as a vaccine in the mouse model. SmSLP-1 formu-
lated with Freund’s adjuvant was utilized in a vaccination trial, and
despite the presence of high antibody titers in immunized mice,
adult worms, and eggs recovered from vaccinated animals were the
same as in control group (68). Unfortunately, not all gut proteins
tested as vaccine were successful.
CONCLUDING REMARKS AND FUTURE PERSPECTIVES
Hematophagous parasite S. mansoni succeeds in the tough job of
surviving inside human host and this success can be attributed,
among other abilities, to their capacity of actively feed via the
digestive tract. Blood processing and nutrient uptake are critical
Table 1 | Digestive tract antigens.
Localization Antigen Vaccine formulation Functions likely affected by
vaccination
Worm burden
reduction
Esophageal gland Sm10.3 Recombinant protein Initial blood processing 32%
Gut lumen Cathepsin B Recombinant protein Hemoglobin processing Up to 84%
SmAE DNA vaccine Hemoglobin processing Nonea
Cathepsin D Synthetic peptides Apical processing of hemoglobin –
Gastrodermis Superoxide dismutaseb DNA vaccine Antioxidant mechanisms; protection from
hemoglobin oxidation products
Up to 54%
Syntenin Recombinant protein Cellular trafficking and biogenesis of small
extracellular vesicles
Up to 37%
Saposin Recombinant protein Lipid binding, transport, and uptake None
a32% reduction in recovered eggs.
bAlso identified in the tegument.
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FIGURE 1 | Schematic representation of S. mansoni emphasizing the
digestive tract and its antigens tested as vaccine. Esophagus is
represented in red, esophageal glands are green, gut lumen is black, and
gastrodermis is gray. The reproductive organs, which are surrounded by the
bifurcated gut, are represented in blue. The tegument is brown, as well as the
oral and ventral suckers. The antigens are listed under the location they were
identified in italics. Superoxide dismutase was identified both in the tegument
and in the digestive tract.
for the survival of schistosomes and direct or indirect interruption
of these processes may represent a realistic strategy for vaccine
development. These interventions would probably lead worms to
starvation, and consequently death, since insufficient supply of
energy impairs growth, pairing, maturation, and fecundity. Here,
we described the physiological function of S. mansoni alimentary
tract and also reported some examples of successful vaccines for-
mulated with digestive tract proteins, summarized in Table 1 and
Figure 1.
The efficacy of these vaccines seems to remain on the gen-
eration of antibodies that are able to bind to the target enzyme
and inhibit its enzymatic function in the parasites, compromising
essential aspects of their biology. The gut lumen seems a hostile
site for antibodies due to its low pH and the presence of multi-
ples proteases. These features are probably the reasons why not
all antigens conferred protection. However, despite the aggressive
environment of the gut, immunization experiments showed that
targeting molecules from digestive tract successfully yielded some
protection against schistosomes. We are still in the beginning of
understanding the complex feeding mechanisms by which schis-
tosomes obtain nutrients from their host and we have no clue if
antibodies are able to affect this process. However, we do know that
infected patients generate high levels of antibodies against the gut
secreted polysaccharide antigens circulating anodic and cathodic
antigens (CCA and CAA), used in diagnostic tests (69), and also
against the gut protease SmCB1 (53). These data indicate that gut
antigens are somehow available to antigen presentation.
Proteomic analyses on schistosomes gut secretions revealed
many cathepsins and other peptidases involved in the proteolytic
pathways of host nutrients. The proteolytic pathways for hemoglo-
bin and albumin have been described and they showed that a large
number of proteases provide some redundancy (28). Functional
redundancy is an issue for the development of vaccines based on
gut proteases; however, this issue could be amended by formulat-
ing a vaccine comprising either a combination of proteases or a
chimeric antigen consisting of epitopes of different enzymes (26).
The better understanding of nutrient uptake and the advancement
of new vaccination approaches are key points for the development
of intervention strategies, specially the development of a vaccine.
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